查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1769903

药物警戒市场（阶段：临床前、I 期、II 期、III 期和 IV 期）；类型：治疗领域、最终用途及其他 - 全球产业分析、规模、份额、成长、趋势及预测，2025 年至 2035 年

Pharmacovigilance Market (Phase: Pre-clinical, Phase I, Phase II, Phase III and Phase IV); Type: Therapeutic Area, and End-use, and Others - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025-2035
出版日期: | 出版商: Transparency Market Research | 英文 228 Pages | 商品交期: 2-10个工作天内

价格

药物警戒市场 - 报告范围

TMR 的全球药物警戒市场报告研究了过去和当前的成长趋势和机会，旨在深入了解 2025 年至 2035 年预测期内的市场指标。该报告提供了 2019 年至 2035 年期间全球药物警戒市场的收入，以 2025 年为基准年，2035 年为预测年。该报告还提供了 2025 年至 2035 年全球药物警戒市场的年复合成长率(CAGR%)。

本报告经过广泛调查后编写。一手研究占据了大部分研究工作，其中分析师对关键意见领袖、行业领导者和舆论领袖进行了访谈。二手研究则参考了主要参与者的产品说明书、年度报告、新闻稿和相关文件，以了解药物警戒市场。

市场概况
2024 年的市场价值 83亿美元
2035年的市场价值 194亿美元
复合年增长率 7.9%

本报告深入探讨了全球药物警戒市场的竞争格局。该报告确定了全球药物警戒市场的主要参与者，并根据不同属性对每位参与者进行了分析。本报告对全球药物警戒市场参与者的属性进行了分析，内容包括公司概况、财务状况、近期发展和 SWOT 分析。

目录

第一章：前言

第二章：假设与研究方法

第三章：执行摘要：全球市场

第四章：市场概览

  • 介绍
  • 概述
  • 市场动态
  • 2020 年至 2035 年全球药物警戒市场分析与预测

第五章：关键见解

  • 政府安全用药措施概述
  • 各主要地区/国家药品不良反应发生率
  • 各地区/国家监管情况
  • 在药物开发过程中的作用
  • 药物警戒报告的比较分析
  • 资金和投资
  • 重要产业事件（合併、收购、合作、协作等）
  • 波特五力分析
  • PESTEL分析
  • 价值链分析

第六章：全球市场分析与预测：分阶段

  • 介绍和定义
  • 主要发现/进展
  • 市场价值预测：分阶段，2020年至2035年
    • 临床前
    • 第一阶段
    • 第二阶段
    • 第三阶段
    • 第四阶段
  • 市场吸引力分析：分阶段

第七章：全球市场分析与预测：依类型

  • 介绍和定义
  • 主要发现/进展
  • 市场价值预测：按类型，2020 年至 2035 年
    • 自发性报告
    • 针对性的报告
    • 群组事件监控
    • 流行病学研究
    • 上市后监测
  • 市场吸引力分析：按类型

第八章：全球市场分析与预测：以交付方式

  • 介绍和定义
  • 主要发现/进展
  • 市场价值预测：以交付方式，2020 年至 2035 年
    • 内部
    • 合约外包
  • 市场吸引力分析：以配送方式

第九章：全球市场分析及预测：依治疗领域

  • 介绍和定义
  • 主要发现/进展
  • 市场价值预测：依治疗领域，2020 年至 2035 年
    • 肿瘤学
    • 神经病学
    • 心臟病学
    • 呼吸系统
    • 自体免疫疾病
    • 其他的
  • 市场吸引力分析：按治疗领域

第十章：全球市场分析与预测：依最终用户

  • 介绍和定义
  • 主要发现/进展
  • 市场价值预测：按最终用户，2020 年至 2035 年
    • 製药和生物技术公司
    • 合约研究组织（CRO）
    • 其他的
  • 市场吸引力分析：按最终用户

第 11 章：全球市场分析与预测：按地区

  • 主要发现
  • 市场价值预测：按地区，2020年至2035年
    • 北美洲
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲
  • 市场吸引力分析：按地区

第十二章：北美市场分析与预测

第十三章：欧洲市场分析与预测

第十四章：亚太市场分析与预测

第十五章：拉丁美洲市场分析与预测

第 16 章：中东和非洲市场分析与预测

第 17 章：竞争格局

  • 市场参与者 - 竞争矩阵（依公司层级和规模）
  • 市占率分析：按公司（2024年）
  • 公司简介
    • Accenture
    • IQVIA Inc.
    • Cognizant
    • Linical
    • ArisGlobal
    • ITClinical
    • ICON plc.
    • TAKE Solutions Limited
    • Parexel International (MA) Corporation
    • Wipro
    • United BioSource LLC
    • Ergomed Group
    • Quanticate
Product Code: TMRGL86696

Pharmacovigilance Market - Scope of Report

TMR's report on the global pharmacovigilance market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2025 to 2035. The report provides revenue of the global pharmacovigilance market for the period 2019-2035, considering 2025 as the base year and 2035 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global pharmacovigilance market from 2025 to 2035.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the pharmacovigilance market.

Market Snapshot
Market Value in 2024US$ 8.3 Bn
Market Value in 2035US$ 19.4 Bn
CAGR7.9%

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global pharmacovigilance market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global pharmacovigilance market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global pharmacovigilance market.

The report delves into the competitive landscape of the global pharmacovigilance market. Key players operating in the global pharmacovigilance market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global pharmacovigilance market profiled in this report.

Key Questions Answered in Global pharmacovigilance Market Report:

  • What is the sales/revenue generated by pharmacovigilance across all regions during the forecast period?
  • What are the opportunities in the global pharmacovigilance market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2035?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Pharmacovigilance Market - Research Objectives and Research Approach

The comprehensive report on the global pharmacovigilance market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global pharmacovigilance market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2035 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global pharmacovigilance market.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Pharmacovigilance Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Segment Definition
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Pharmacovigilance Market Analysis and Forecast, 2020 to 2035
    • 4.4.1. Market Revenue Projections (US$ Mn)

5. Key Insights

  • 5.1. Overview of Government Initiatives in Safe Medicine Use
  • 5.2. Rate of Adverse Drug Reactions By Key Region/Countries
  • 5.3. Regulatory Scenario by Region/Country
  • 5.4. Role of Pharmacovigilance during Drug Development Process
  • 5.5. Comparative Analysis of Report used in Pharmacovigilance
  • 5.6. Funding and Investments
  • 5.7. Key Industry Events (Mergers, Acquisitions, Partnerships, Collaborations, etc.)
  • 5.8. PORTER's Five Forces Analysis
  • 5.9. PESTEL Analysis
  • 5.10. Value Chain Analysis

6. Global Pharmacovigilance Market Analysis and Forecast, by Phase

  • 6.1. Introduction & Definition
  • 6.2. Key Findings/Developments
  • 6.3. Market Value Forecast, by Phase, 2020 to 2035
    • 6.3.1. Pre-clinical
    • 6.3.2. Phase I
    • 6.3.3. Phase II
    • 6.3.4. Phase III
    • 6.3.5. Phase IV
  • 6.4. Market Attractiveness Analysis, by Phase

7. Global Pharmacovigilance Market Analysis and Forecast, by Type

  • 7.1. Introduction & Definition
  • 7.2. Key Findings/Developments
  • 7.3. Market Value Forecast, by Type, 2020 to 2035
    • 7.3.1. Spontaneous Reporting
    • 7.3.2. Targeted Reporting
    • 7.3.3. Cohort Event Monitoring
    • 7.3.4. Epidemiological Studies
    • 7.3.5. Post-Marketing Surveillance
  • 7.4. Market Attractiveness Analysis, by Type

8. Global Pharmacovigilance Market Analysis and Forecast, by Delivery Mode

  • 8.1. Introduction & Definition
  • 8.2. Key Findings/Developments
  • 8.3. Market Value Forecast, by Delivery Mode, 2020 to 2035
    • 8.3.1. In-house
    • 8.3.2. Contract Outsourcing
  • 8.4. Market Attractiveness Analysis, by Delivery Mode

9. Global Pharmacovigilance Market Analysis and Forecast, by Therapeutic Area

  • 9.1. Introduction & Definition
  • 9.2. Key Findings/Developments
  • 9.3. Market Value Forecast, by Therapeutic Area, 2020 to 2035
    • 9.3.1. Oncology
    • 9.3.2. Neurology
    • 9.3.3. Cardiology
    • 9.3.4. Respiratory Systems
    • 9.3.5. Autoimmune Diseases
    • 9.3.6. Others
  • 9.4. Market Attractiveness Analysis, by Therapeutic Area

10. Global Pharmacovigilance Market Analysis and Forecast, by End-user

  • 10.1. Introduction & Definition
  • 10.2. Key Findings/Developments
  • 10.3. Market Value Forecast, by End-user, 2020 to 2035
    • 10.3.1. Pharmaceutical & Biotechnology Companies
    • 10.3.2. Contract Research Organizations (CROs)
    • 10.3.3. Others
  • 10.4. Market Attractiveness Analysis, by End-user

11. Global Pharmacovigilance Market Analysis and Forecast, by Region

  • 11.1. Key Findings
  • 11.2. Market Value Forecast, by Region, 2020 to 2035
    • 11.2.1. North America
    • 11.2.2. Europe
    • 11.2.3. Asia Pacific
    • 11.2.4. Latin America
    • 11.2.5. Middle East & Africa
  • 11.3. Market Attractiveness Analysis, by Region

12. North America Pharmacovigilance Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Market Value Forecast, by Phase, 2020 to 2035
    • 12.2.1. Pre-clinical
    • 12.2.2. Phase I
    • 12.2.3. Phase II
    • 12.2.4. Phase III
    • 12.2.5. Phase IV
  • 12.3. Market Value Forecast, by Type, 2020 to 2035
    • 12.3.1. Spontaneous Reporting
    • 12.3.2. Targeted Reporting
    • 12.3.3. Cohort Event Monitoring
    • 12.3.4. Epidemiological Studies
    • 12.3.5. Post-Marketing Surveillance
  • 12.4. Market Value Forecast, by Delivery Mode, 2020 to 2035
    • 12.4.1. In-house
    • 12.4.2. Contract Outsourcing
  • 12.5. Market Value Forecast, by Therapeutic Area, 2020 to 2035
    • 12.5.1. Oncology
    • 12.5.2. Neurology
    • 12.5.3. Cardiology
    • 12.5.4. Respiratory Systems
    • 12.5.5. Autoimmune Diseases
    • 12.5.6. Others
  • 12.6. Market Value Forecast, by End-user, 2020 to 2035
    • 12.6.1. Pharmaceutical & Biotechnology Companies
    • 12.6.2. Contract Research Organizations (CROs)
    • 12.6.3. Others
  • 12.7. Market Value Forecast, by Country, 2020 to 2035
    • 12.7.1. U.S.
    • 12.7.2. Canada
  • 12.8. Market Attractiveness Analysis
    • 12.8.1. By Phase
    • 12.8.2. By Type
    • 12.8.3. By Delivery Mode
    • 12.8.4. By Therapeutic Area
    • 12.8.5. By End-user
    • 12.8.6. By Country

13. Europe Pharmacovigilance Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Market Value Forecast, by Phase, 2020 to 2035
    • 13.2.1. Pre-clinical
    • 13.2.2. Phase I
    • 13.2.3. Phase II
    • 13.2.4. Phase III
    • 13.2.5. Phase IV
  • 13.3. Market Value Forecast, by Type, 2020 to 2035
    • 13.3.1. Spontaneous Reporting
    • 13.3.2. Targeted Reporting
    • 13.3.3. Cohort Event Monitoring
    • 13.3.4. Epidemiological Studies
    • 13.3.5. Post-Marketing Surveillance
  • 13.4. Market Value Forecast, by Delivery Mode, 2020 to 2035
    • 13.4.1. In-house
    • 13.4.2. Contract Outsourcing
  • 13.5. Market Value Forecast, by Therapeutic Area, 2020 to 2035
    • 13.5.1. Oncology
    • 13.5.2. Neurology
    • 13.5.3. Cardiology
    • 13.5.4. Respiratory Systems
    • 13.5.5. Autoimmune Diseases
    • 13.5.6. Others
  • 13.6. Market Value Forecast, by End-user, 2020 to 2035
    • 13.6.1. Pharmaceutical & Biotechnology Companies
    • 13.6.2. Contract Research Organizations (CROs)
    • 13.6.3. Others
  • 13.7. Market Value Forecast, by Country/Sub-region, 2020 to 2035
    • 13.7.1. Germany
    • 13.7.2. UK
    • 13.7.3. France
    • 13.7.4. Italy
    • 13.7.5. Spain
    • 13.7.6. Rest of Europe
  • 13.8. Market Attractiveness Analysis
    • 13.8.1. By Phase
    • 13.8.2. By Type
    • 13.8.3. By Delivery Mode
    • 13.8.4. By Therapeutic Area
    • 13.8.5. By End-user
    • 13.8.6. By Country/Sub-region

14. Asia Pacific Pharmacovigilance Market Analysis and Forecast

  • 14.1. Introduction
    • 14.1.1. Key Findings
  • 14.2. Market Value Forecast, by Phase, 2020 to 2035
    • 14.2.1. Pre-clinical
    • 14.2.2. Phase I
    • 14.2.3. Phase II
    • 14.2.4. Phase III
    • 14.2.5. Phase IV
  • 14.3. Market Value Forecast, by Type, 2020 to 2035
    • 14.3.1. Spontaneous Reporting
    • 14.3.2. Targeted Reporting
    • 14.3.3. Cohort Event Monitoring
    • 14.3.4. Epidemiological Studies
    • 14.3.5. Post-Marketing Surveillance
  • 14.4. Market Value Forecast, by Delivery Mode, 2020 to 2035
    • 14.4.1. In-house
    • 14.4.2. Contract Outsourcing
  • 14.5. Market Value Forecast, by Therapeutic Area, 2020 to 2035
    • 14.5.1. Oncology
    • 14.5.2. Neurology
    • 14.5.3. Cardiology
    • 14.5.4. Respiratory Systems
    • 14.5.5. Autoimmune Diseases
    • 14.5.6. Others
  • 14.6. Market Value Forecast, by End-user, 2020 to 2035
    • 14.6.1. Pharmaceutical & Biotechnology Companies
    • 14.6.2. Contract Research Organizations (CROs)
    • 14.6.3. Others
  • 14.7. Market Value Forecast, by Country/Sub-region, 2020 to 2035
    • 14.7.1. China
    • 14.7.2. Japan
    • 14.7.3. India
    • 14.7.4. Australia & New Zealand
    • 14.7.5. Rest of Asia Pacific
  • 14.8. Market Attractiveness Analysis
    • 14.8.1. By Phase
    • 14.8.2. By Type
    • 14.8.3. By Delivery Mode
    • 14.8.4. By Therapeutic Area
    • 14.8.5. By End-user
    • 14.8.6. By Country/Sub-region

15. Latin America Pharmacovigilance Market Analysis and Forecast

  • 15.1. Introduction
    • 15.1.1. Key Findings
  • 15.2. Market Value Forecast, by Phase, 2020 to 2035
    • 15.2.1. Pre-clinical
    • 15.2.2. Phase I
    • 15.2.3. Phase II
    • 15.2.4. Phase III
    • 15.2.5. Phase IV
  • 15.3. Market Value Forecast, by Type, 2020 to 2035
    • 15.3.1. Spontaneous Reporting
    • 15.3.2. Targeted Reporting
    • 15.3.3. Cohort Event Monitoring
    • 15.3.4. Epidemiological Studies
    • 15.3.5. Post-Marketing Surveillance
  • 15.4. Market Value Forecast, by Delivery Mode, 2020 to 2035
    • 15.4.1. In-house
    • 15.4.2. Contract Outsourcing
  • 15.5. Market Value Forecast, by Therapeutic Area, 2020 to 2035
    • 15.5.1. Oncology
    • 15.5.2. Neurology
    • 15.5.3. Cardiology
    • 15.5.4. Respiratory Systems
    • 15.5.5. Autoimmune Diseases
    • 15.5.6. Others
  • 15.6. Market Value Forecast, by End-user, 2020 to 2035
    • 15.6.1. Pharmaceutical & Biotechnology Companies
    • 15.6.2. Contract Research Organizations (CROs)
    • 15.6.3. Others
  • 15.7. Market Value Forecast, by Country/Sub-region, 2020 to 2035
    • 15.7.1. Brazil
    • 15.7.2. Mexico
    • 15.7.3. Rest of Latin America
  • 15.8. Market Attractiveness Analysis
    • 15.8.1. By Phase
    • 15.8.2. By Type
    • 15.8.3. By Delivery Mode
    • 15.8.4. By Therapeutic Area
    • 15.8.5. By End-user
    • 15.8.6. By Country/Sub-region

16. Middle East & Africa Pharmacovigilance Market Analysis and Forecast

  • 16.1. Introduction
    • 16.1.1. Key Findings
  • 16.2. Market Value Forecast, by Phase, 2020 to 2035
    • 16.2.1. Pre-clinical
    • 16.2.2. Phase I
    • 16.2.3. Phase II
    • 16.2.4. Phase III
    • 16.2.5. Phase IV
  • 16.3. Market Value Forecast, by Type, 2020 to 2035
    • 16.3.1. Spontaneous Reporting
    • 16.3.2. Targeted Reporting
    • 16.3.3. Cohort Event Monitoring
    • 16.3.4. Epidemiological Studies
    • 16.3.5. Post-Marketing Surveillance
  • 16.4. Market Value Forecast, by Delivery Mode, 2020 to 2035
    • 16.4.1. In-house
    • 16.4.2. Contract Outsourcing
  • 16.5. Market Value Forecast, by Therapeutic Area, 2020 to 2035
    • 16.5.1. Oncology
    • 16.5.2. Neurology
    • 16.5.3. Cardiology
    • 16.5.4. Respiratory Systems
    • 16.5.5. Autoimmune Diseases
    • 16.5.6. Others
  • 16.6. Market Value Forecast, by End-user, 2020 to 2035
    • 16.6.1. Pharmaceutical & Biotechnology Companies
    • 16.6.2. Contract Research Organizations (CROs)
    • 16.6.3. Others
  • 16.7. Market Value Forecast, by Country/Sub-region, 2020 to 2035
    • 16.7.1. GCC Countries
    • 16.7.2. South Africa
    • 16.7.3. Rest of Middle East & Africa
  • 16.8. Market Attractiveness Analysis
    • 16.8.1. By Phase
    • 16.8.2. By Type
    • 16.8.3. By Delivery Mode
    • 16.8.4. By Therapeutic Area
    • 16.8.5. By End-user
    • 16.8.6. By Country/Sub-region

17. Competition Landscape

  • 17.1. Market Player - Competition Matrix (By Tier and Size of Companies)
  • 17.2. Market Share Analysis, by Company (2024)
  • 17.3. Company Profiles
    • 17.3.1. Accenture
      • 17.3.1.1. Company Overview
      • 17.3.1.2. Financial Overview
      • 17.3.1.3. Product Portfolio
      • 17.3.1.4. Business Strategies
      • 17.3.1.5. Recent Developments
    • 17.3.2. IQVIA Inc.
      • 17.3.2.1. Company Overview
      • 17.3.2.2. Financial Overview
      • 17.3.2.3. Product Portfolio
      • 17.3.2.4. Business Strategies
      • 17.3.2.5. Recent Developments
    • 17.3.3. Cognizant
      • 17.3.3.1. Company Overview
      • 17.3.3.2. Financial Overview
      • 17.3.3.3. Product Portfolio
      • 17.3.3.4. Business Strategies
      • 17.3.3.5. Recent Developments
    • 17.3.4. Linical
      • 17.3.4.1. Company Overview
      • 17.3.4.2. Financial Overview
      • 17.3.4.3. Product Portfolio
      • 17.3.4.4. Business Strategies
      • 17.3.4.5. Recent Developments
    • 17.3.5. ArisGlobal
      • 17.3.5.1. Company Overview
      • 17.3.5.2. Financial Overview
      • 17.3.5.3. Product Portfolio
      • 17.3.5.4. Business Strategies
      • 17.3.5.5. Recent Developments
    • 17.3.6. ITClinical
      • 17.3.6.1. Company Overview
      • 17.3.6.2. Financial Overview
      • 17.3.6.3. Product Portfolio
      • 17.3.6.4. Business Strategies
      • 17.3.6.5. Recent Developments
    • 17.3.7. ICON plc.
      • 17.3.7.1. Company Overview
      • 17.3.7.2. Financial Overview
      • 17.3.7.3. Product Portfolio
      • 17.3.7.4. Business Strategies
      • 17.3.7.5. Recent Developments
    • 17.3.8. TAKE Solutions Limited
      • 17.3.8.1. Company Overview
      • 17.3.8.2. Financial Overview
      • 17.3.8.3. Product Portfolio
      • 17.3.8.4. Business Strategies
      • 17.3.8.5. Recent Developments
    • 17.3.9. Parexel International (MA) Corporation
      • 17.3.9.1. Company Overview
      • 17.3.9.2. Financial Overview
      • 17.3.9.3. Product Portfolio
      • 17.3.9.4. Business Strategies
      • 17.3.9.5. Recent Developments
    • 17.3.10. Wipro
      • 17.3.10.1. Company Overview
      • 17.3.10.2. Financial Overview
      • 17.3.10.3. Product Portfolio
      • 17.3.10.4. Business Strategies
      • 17.3.10.5. Recent Developments
    • 17.3.11. United BioSource LLC
      • 17.3.11.1. Company Overview
      • 17.3.11.2. Financial Overview
      • 17.3.11.3. Product Portfolio
      • 17.3.11.4. Business Strategies
      • 17.3.11.5. Recent Developments
    • 17.3.12. Ergomed Group
      • 17.3.12.1. Company Overview
      • 17.3.12.2. Financial Overview
      • 17.3.12.3. Product Portfolio
      • 17.3.12.4. Business Strategies
      • 17.3.12.5. Recent Developments
    • 17.3.13. Quanticate
      • 17.3.13.1. Company Overview
      • 17.3.13.2. Financial Overview
      • 17.3.13.3. Product Portfolio
      • 17.3.13.4. Business Strategies
      • 17.3.13.5. Recent Developments

List of Tables

  • Table 01: Global Pharmacovigilance Market Value (US$ Mn) Forecast, By Phase, 2020 to 2035
  • Table 02: Global Pharmacovigilance Market Value (US$ Mn) Forecast, By Type, 2020 to 2035
  • Table 03: Global Pharmacovigilance Market Value (US$ Mn) Forecast, By Delivery Mode, 2020 to 2035
  • Table 04: Global Pharmacovigilance Market Value (US$ Mn) Forecast, By Therapeutic Area, 2020 to 2035
  • Table 05: Global Pharmacovigilance Market Value (US$ Mn) Forecast, By End-user, 2020 to 2035
  • Table 06: Global Pharmacovigilance Market Value (US$ Mn) Forecast, By Region, 2020 to 2035
  • Table 07: North America - Pharmacovigilance Market Value (US$ Mn) Forecast, by Country, 2020 to 2035
  • Table 08: North America Pharmacovigilance Market Value (US$ Mn) Forecast, By Phase, 2020 to 2035
  • Table 09: North America Pharmacovigilance Market Value (US$ Mn) Forecast, By Type, 2020 to 2035
  • Table 10: North America Pharmacovigilance Market Value (US$ Mn) Forecast, By Delivery Mode, 2020 to 2035
  • Table 11: North America Pharmacovigilance Market Value (US$ Mn) Forecast, By Therapeutic Area, 2020 to 2035
  • Table 12: North America Pharmacovigilance Market Value (US$ Mn) Forecast, By End-user, 2020 to 2035
  • Table 13: Europe - Pharmacovigilance Market Value (US$ Mn) Forecast, by Country / Sub-region, 2020 to 2035
  • Table 14: Europe Pharmacovigilance Market Value (US$ Mn) Forecast, By Phase, 2020 to 2035
  • Table 15: Europe Pharmacovigilance Market Value (US$ Mn) Forecast, By Type, 2020 to 2035
  • Table 16: Europe Pharmacovigilance Market Value (US$ Mn) Forecast, By Delivery Mode, 2020 to 2035
  • Table 17: Europe Pharmacovigilance Market Value (US$ Mn) Forecast, By Therapeutic Area, 2020 to 2035
  • Table 18: Europe Pharmacovigilance Market Value (US$ Mn) Forecast, By End-user, 2020 to 2035
  • Table 19: Asia Pacific - Pharmacovigilance Market Value (US$ Mn) Forecast, by Country / Sub-region, 2020 to 2035
  • Table 20: Asia Pacific Pharmacovigilance Market Value (US$ Mn) Forecast, By Phase, 2020 to 2035
  • Table 21: Asia Pacific Pharmacovigilance Market Value (US$ Mn) Forecast, By Type, 2020 to 2035
  • Table 22: Asia Pacific Pharmacovigilance Market Value (US$ Mn) Forecast, By Delivery Mode, 2020 to 2035
  • Table 23: Asia Pacific Pharmacovigilance Market Value (US$ Mn) Forecast, By Therapeutic Area, 2020 to 2035
  • Table 24: Asia Pacific Pharmacovigilance Market Value (US$ Mn) Forecast, By End-user, 2020 to 2035
  • Table 25: Latin America - Pharmacovigilance Market Value (US$ Mn) Forecast, by Country / Sub-region, 2020 to 2035
  • Table 26: Latin America Pharmacovigilance Market Value (US$ Mn) Forecast, By Phase, 2020 to 2035
  • Table 27: Latin America Pharmacovigilance Market Value (US$ Mn) Forecast, By Type, 2020 to 2035
  • Table 28: Latin America Pharmacovigilance Market Value (US$ Mn) Forecast, By Delivery Mode, 2020 to 2035
  • Table 29: Latin America Pharmacovigilance Market Value (US$ Mn) Forecast, By Therapeutic Area, 2020 to 2035
  • Table 30: Latin America Pharmacovigilance Market Value (US$ Mn) Forecast, By End-user, 2020 to 2035
  • Table 31: Middle East & Africa - Pharmacovigilance Market Value (US$ Mn) Forecast, by Country / Sub-region, 2020 to 2035
  • Table 32: Middle East & Africa Pharmacovigilance Market Value (US$ Mn) Forecast, By Phase, 2020 to 2035
  • Table 33: Middle East & Africa Pharmacovigilance Market Value (US$ Mn) Forecast, By Type, 2020 to 2035
  • Table 34: Middle East & Africa Pharmacovigilance Market Value (US$ Mn) Forecast, By Delivery Mode, 2020 to 2035
  • Table 35: Middle East & Africa Pharmacovigilance Market Value (US$ Mn) Forecast, By Therapeutic Area, 2020 to 2035
  • Table 36: Middle East & Africa Pharmacovigilance Market Value (US$ Mn) Forecast, By End-user, 2020 to 2035

List of Figures

  • Figure 01: Global Pharmacovigilance Market Value Share Analysis, By Phase, 2024 and 2035
  • Figure 02: Global Pharmacovigilance Market Attractiveness Analysis, By Phase, 2025 to 2035
  • Figure 03: Global Pharmacovigilance Market Revenue (US$ Mn), by Pre-clinical, 2020 to 2035
  • Figure 04: Global Pharmacovigilance Market Revenue (US$ Mn), by Phase I, 2020 to 2035
  • Figure 05: Global Pharmacovigilance Market Revenue (US$ Mn), by Phase II, 2020 to 2035
  • Figure 06: Global Pharmacovigilance Market Revenue (US$ Mn), by Phase III, 2020 to 2035
  • Figure 07: Global Pharmacovigilance Market Revenue (US$ Mn), by Phase v, 2020 to 2035
  • Figure 08: Global Pharmacovigilance Market Value Share Analysis, By Type, 2024 and 2035
  • Figure 09: Global Pharmacovigilance Market Attractiveness Analysis, By Type, 2025 to 2035
  • Figure 10: Global Pharmacovigilance Market Revenue (US$ Mn), by Spontaneous Reporting, 2020 to 2035
  • Figure 11: Global Pharmacovigilance Market Revenue (US$ Mn), by Targeted Reporting, 2020 to 2035
  • Figure 12: Global Pharmacovigilance Market Revenue (US$ Mn), by Cohort Event Monitoring, 2020 to 2035
  • Figure 13: Global Pharmacovigilance Market Revenue (US$ Mn), by Epidemiological Studies, 2020 to 2035
  • Figure 14: Global Pharmacovigilance Market Revenue (US$ Mn), by Post-Marketing Surveillance, 2020 to 2035
  • Figure 15: Global Pharmacovigilance Market Value Share Analysis, By Delivery Mode, 2024 and 2035
  • Figure 16: Global Pharmacovigilance Market Attractiveness Analysis, By Delivery Mode, 2025 to 2035
  • Figure 17: Global Pharmacovigilance Market Revenue (US$ Mn), by In-house, 2020 to 2035
  • Figure 18: Global Pharmacovigilance Market Revenue (US$ Mn), by Contract Outsourcing, 2020 to 2035
  • Figure 19: Global Pharmacovigilance Market Value Share Analysis, By Therapeutic Area, 2024 and 2035
  • Figure 20: Global Pharmacovigilance Market Attractiveness Analysis, By Therapeutic Area, 2025 to 2035
  • Figure 21: Global Pharmacovigilance Market Revenue (US$ Mn), by Oncology, 2020 to 2035
  • Figure 22: Global Pharmacovigilance Market Revenue (US$ Mn), by Neurology, 2020 to 2035
  • Figure 23: Global Pharmacovigilance Market Revenue (US$ Mn), by Cardiology, 2020 to 2035
  • Figure 24: Global Pharmacovigilance Market Revenue (US$ Mn), by Respiratory Systems, 2020 to 2035
  • Figure 25: Global Pharmacovigilance Market Revenue (US$ Mn), by Autoimmune Diseases, 2020 to 2035
  • Figure 26: Global Pharmacovigilance Market Revenue (US$ Mn), by Others, 2020 to 2035
  • Figure 27: Global Pharmacovigilance Market Value Share Analysis, By End-user, 2024 and 2035
  • Figure 28: Global Pharmacovigilance Market Attractiveness Analysis, By End-user, 2025 to 2035
  • Figure 29: Global Pharmacovigilance Market Revenue (US$ Mn), by Pharmaceutical & Biotechnology Companies, 2020 to 2035
  • Figure 30: Global Pharmacovigilance Market Revenue (US$ Mn), by Contract Research Organizations (CROs), 2020 to 2035
  • Figure 31: Global Pharmacovigilance Market Revenue (US$ Mn), by Others 2020 to 2035
  • Figure 32: Global Pharmacovigilance Market Value Share Analysis, By Region, 2024 and 2035
  • Figure 33: Global Pharmacovigilance Market Attractiveness Analysis, By Region, 2025 to 2035
  • Figure 34: North America - Pharmacovigilance Market Value (US$ Mn) Forecast, 2020 to 2035
  • Figure 35: North America - Pharmacovigilance Market Value Share Analysis, by Country, 2024 and 2035
  • Figure 36: North America - Pharmacovigilance Market Attractiveness Analysis, by Country, 2025 to 2035
  • Figure 37: North America Pharmacovigilance Market Value Share Analysis, By Phase, 2024 and 2035
  • Figure 38: North America Pharmacovigilance Market Attractiveness Analysis, By Phase, 2025 to 2035
  • Figure 39: North America Pharmacovigilance Market Value Share Analysis, By Type, 2024 and 2035
  • Figure 40: North America Pharmacovigilance Market Attractiveness Analysis, By Type, 2025 to 2035
  • Figure 41: North America Pharmacovigilance Market Value Share Analysis, By Delivery Mode, 2024 and 2035
  • Figure 42: North America Pharmacovigilance Market Attractiveness Analysis, By Delivery Mode, 2025 to 2035
  • Figure 43: North America Pharmacovigilance Market Value Share Analysis, By Therapeutic Area, 2024 and 2035
  • Figure 44: North America Pharmacovigilance Market Attractiveness Analysis, By Therapeutic Area, 2025 to 2035
  • Figure 45: North America Pharmacovigilance Market Value Share Analysis, By End-user, 2024 and 2035
  • Figure 46: North America Pharmacovigilance Market Attractiveness Analysis, By End-user, 2025 to 2035
  • Figure 47: Europe - Pharmacovigilance Market Value (US$ Mn) Forecast, 2020 to 2035
  • Figure 48: Europe - Pharmacovigilance Market Value Share Analysis, by Country / Sub-region, 2024 and 2035
  • Figure 49: Europe - Pharmacovigilance Market Attractiveness Analysis, by Country / Sub-region, 2025 to 2035
  • Figure 50: Europe Pharmacovigilance Market Value Share Analysis, By Phase, 2024 and 2035
  • Figure 51: Europe Pharmacovigilance Market Attractiveness Analysis, By Phase, 2025 to 2035
  • Figure 52: Europe Pharmacovigilance Market Value Share Analysis, By Type, 2024 and 2035
  • Figure 53: Europe Pharmacovigilance Market Attractiveness Analysis, By Type, 2025 to 2035
  • Figure 54: Europe Pharmacovigilance Market Value Share Analysis, By Delivery Mode, 2024 and 2035
  • Figure 55: Europe Pharmacovigilance Market Attractiveness Analysis, By Delivery Mode, 2025 to 2035
  • Figure 56: Europe Pharmacovigilance Market Value Share Analysis, By Therapeutic Area, 2024 and 2035
  • Figure 57: Europe Pharmacovigilance Market Attractiveness Analysis, By Therapeutic Area, 2025 to 2035
  • Figure 58: Europe Pharmacovigilance Market Value Share Analysis, By End-user, 2024 and 2035
  • Figure 59: Europe Pharmacovigilance Market Attractiveness Analysis, By End-user, 2025 to 2035
  • Figure 60: Asia Pacific - Pharmacovigilance Market Value (US$ Mn) Forecast, 2020 to 2035
  • Figure 61: Asia Pacific - Pharmacovigilance Market Value Share Analysis, by Country/Sub-region, 2024 and 2035
  • Figure 62: Asia Pacific - Pharmacovigilance Market Attractiveness Analysis, by Country/Sub-region, 2025 to 2035
  • Figure 63: Asia Pacific Pharmacovigilance Market Value Share Analysis, By Phase, 2024 and 2035
  • Figure 64: Asia Pacific Pharmacovigilance Market Attractiveness Analysis, By Phase, 2025 to 2035
  • Figure 65: Asia Pacific Pharmacovigilance Market Value Share Analysis, By Type, 2024 and 2035
  • Figure 66: Asia Pacific Pharmacovigilance Market Attractiveness Analysis, By Type, 2025 to 2035
  • Figure 67: Asia Pacific Pharmacovigilance Market Value Share Analysis, By Delivery Mode, 2024 and 2035
  • Figure 68: Asia Pacific Pharmacovigilance Market Attractiveness Analysis, By Delivery Mode, 2025 to 2035
  • Figure 69: Asia Pacific Pharmacovigilance Market Value Share Analysis, By Therapeutic Area, 2024 and 2035
  • Figure 70: Asia Pacific Pharmacovigilance Market Attractiveness Analysis, By Therapeutic Area, 2025 to 2035
  • Figure 71: Asia Pacific Pharmacovigilance Market Value Share Analysis, By End-user, 2024 and 2035
  • Figure 72: Asia Pacific Pharmacovigilance Market Attractiveness Analysis, By End-user, 2025 to 2035
  • Figure 73: Latin America - Pharmacovigilance Market Value (US$ Mn) Forecast, 2020 to 2035
  • Figure 74: Latin America - Pharmacovigilance Market Value Share Analysis, by Country / Sub-region, 2024 and 2035
  • Figure 75: Latin America - Pharmacovigilance Market Attractiveness Analysis, by Country / Sub-region, 2025 to 2035
  • Figure 76: Latin America Pharmacovigilance Market Value Share Analysis, By Phase, 2024 and 2035
  • Figure 77: Latin America Pharmacovigilance Market Attractiveness Analysis, By Phase, 2025 to 2035
  • Figure 78: Latin America Pharmacovigilance Market Value Share Analysis, By Type, 2024 and 2035
  • Figure 79: Latin America Pharmacovigilance Market Attractiveness Analysis, By Type, 2025 to 2035
  • Figure 80: Latin America Pharmacovigilance Market Value Share Analysis, By Delivery Mode, 2024 and 2035
  • Figure 81: Latin America Pharmacovigilance Market Attractiveness Analysis, By Delivery Mode, 2025 to 2035
  • Figure 82: Latin America Pharmacovigilance Market Value Share Analysis, By Therapeutic Area, 2024 and 2035
  • Figure 83: Latin America Pharmacovigilance Market Attractiveness Analysis, By Therapeutic Area, 2025 to 2035
  • Figure 84: Latin America Pharmacovigilance Market Value Share Analysis, By End-user, 2024 and 2035
  • Figure 85: Latin America Pharmacovigilance Market Attractiveness Analysis, By End-user, 2025 to 2035
  • Figure 86: Middle East & Africa - Pharmacovigilance Market Value (US$ Mn) Forecast, 2020 to 2035
  • Figure 87: Middle East & Africa - Pharmacovigilance Market Value Share Analysis, by Country / Sub-region, 2024 and 2035
  • Figure 88: Middle East & Africa - Pharmacovigilance Market Attractiveness Analysis, by Country / Sub-region, 2025 to 2035
  • Figure 89: Middle East & Africa Pharmacovigilance Market Value Share Analysis, By Phase, 2024 and 2035
  • Figure 90: Middle East & Africa Pharmacovigilance Market Attractiveness Analysis, By Phase, 2025 to 2035
  • Figure 91: Middle East & Africa Pharmacovigilance Market Value Share Analysis, By Type, 2024 and 2035
  • Figure 92: Middle East & Africa Pharmacovigilance Market Attractiveness Analysis, By Type, 2025 to 2035
  • Figure 93: Middle East & Africa Pharmacovigilance Market Value Share Analysis, By Delivery Mode, 2024 and 2035
  • Figure 94: Middle East & Africa Pharmacovigilance Market Attractiveness Analysis, By Delivery Mode, 2025 to 2035
  • Figure 95: Middle East & Africa Pharmacovigilance Market Value Share Analysis, By Therapeutic Area, 2024 and 2035
  • Figure 96: Middle East & Africa Pharmacovigilance Market Attractiveness Analysis, By Therapeutic Area, 2025 to 2035
  • Figure 97: Middle East & Africa Pharmacovigilance Market Value Share Analysis, By End-user, 2024 and 2035
  • Figure 98: Middle East & Africa Pharmacovigilance Market Attractiveness Analysis, By End-user, 2025 to 2035